Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesTSXV:ZYUS 16 EV-to-FCF is -7.89 as of Jul. 21, 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 566 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 176678.27% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ZYUS Life Sciences's Enterprise Value is C$61.46 Mil.
ZYUS Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$-7.79 Mil. Therefore, ZYUS Life Sciences's EV-to-FCF for today is -7.89.
The historical rank and industry rank for ZYUS Life Sciences's EV-to-FCF or its related term are showing as below:
TSXV:ZYUS'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.73 Med: -5.45 Max: -3.32
Current: -5.07
During the past 5 years, the highest EV-to-FCF of ZYUS Life Sciences was -3.32. The lowest was -17.73. And the median was -5.45.
TSXV:ZYUS's EV-to-FCF is ranked worse than 100% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs TSXV:ZYUS: -5.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ZYUS Life Sciences (TSXV:ZYUS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ZYUS Life Sciences's PE Ratio (TTM) for today is calculated as:
ZYUS Life Sciences's share price for today is C$0.495.
ZYUS Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ZYUS Life Sciences EV-to-FCF Related Terms
ZYUS Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ZYUS Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EV-to-FCF falls into.
ZYUS Life Sciences's current Enterprise Value is C$61.46 Mil.
ZYUS Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-7.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (TSXV:ZYUS) has a EV-to-FCF of -7.89 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ZYUS Life Sciences and its competitors. According to the industry distribution chart, ZYUS Life Sciences ranks #999999 out of 566 companies in the Drug Manufacturers industry.
Is ZYUS Life Sciences' EV-to-FCF too high?
ZYUS Life Sciences' current EV-to-FCF is -7.89. Based on the distribution chart, ZYUS Life Sciences ranks #999999 out of 566 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #999999 out of 566 companies for EV-to-FCF. This places ZYUS Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 20.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.95, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current EV-to-FCF is -7.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current EV-to-FCF of -7.89. The current EV-to-FCF is -7.89. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current EV-to-FCF is -7.89 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score
Get the complete analysis for TSXV:ZYUS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:ZYUS has been successfully added to your 
